Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.10 - Poster Session 1 - Chemotherapy
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 57
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.10-032 - Sensitivity and meta-regression analysis exploring potential outcomes predictors in randomized trials (RCTs) evaluating the benefit of 1st-line tyrosine kinase inhibitors (TKIs) for epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma.
09:30 - 09:30 | Author(s): S. Pilotto
- Abstract
Loading...
-
+
P1.11 - Poster Session 1 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 45
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.11-033 - Afatinib in EGFR mutant non-small-cell lung cancer patients with acquired resistance to reversible EGFR-TKIs
09:30 - 09:30 | Author(s): F. Cappuzzo
- Abstract
Loading...
-
+
O01 - Prognostic and Predictive Biomarkers I
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:T. Mitsudomi
- Coordinates: 10/28/2013, 10:30 - 12:00, Parkside Auditorium, Level 1
-
+
O01.07 - Randomized Proteomic Stratified Phase III Study of Second Line Erlotinib (E) versus Chemotherapy (CT) in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE): Secondary Endpoint Analysis
11:35 - 11:45 | Author(s): V. Gregorc
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.08 - Poster Session 2 - Radiotherapy
- Type: Poster Session
- Track: Radiation Oncology + Radiotherapy
- Presentations: 27
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.08-019 - Palliative radiation during pemetrexed plus cisplatin first-line treatment or pemetrexed continuation maintenance treatment in advanced nonsquamous non-small cell lung cancer (NSCLC): A report of patient safety in the PARAMOUNT trial
09:30 - 09:30 | Author(s): F. De Marinis
- Abstract
Loading...
-
+
P2.10 - Poster Session 2 - Chemotherapy
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 52
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.10-037 - Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after completing at least 4 cycles of pemetrexed plus cisplatin induction treatment: a cross-trial analysis of two phase III trials
09:30 - 09:30 | Author(s): G.V. Scagliotti
- Abstract
Loading...
-
+
O15 - NSCLC - Chemotherapy II
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:G. Richardson
- Coordinates: 10/29/2013, 10:30 - 12:00, Bayside Auditorium A, Level 1
-
+
O15.06 - Randomized Phase III Trial of Gemcitabine (G)/Carboplatin (C) with or without Iniparib (I) in Patients (Pts) with Previously Untreated Stage IV Squamous Lung Cancer
11:25 - 11:35 | Author(s): D. Spigel
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
O16 - NSCLC - Targeted Therapies III
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:H.A. Wakelee
- Coordinates: 10/29/2013, 10:30 - 12:00, Parkside Auditorium, Level 1
-
+
O16.03 - Cost-utility analysis of first-line treatment with erlotinib versus chemotherapy in EGFR-mutant advanced non-small-cell lung cancer (NSCLC): economic analysis of EURTAC trial
10:50 - 11:00 | Author(s): A. Vergnenegre
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MO21 - Prognostic and Predictive Biomarkers V - EGFR
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 12
- Moderators:D.C. Lam
- Coordinates: 10/30/2013, 10:30 - 12:00, Bayside Auditorium A, Level 1
-
+
MO21.01 - Randomized Proteomic Stratified Phase III Study of Second Line Erlotinib (E) versus Chemotherapy (CT) in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE): VeriStrat analysis of longitudinal samples
10:30 - 10:35 | Author(s): A. Bulotta
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MO26 - Anatomical Pathology II
- Type: Mini Oral Abstract Session
- Track: Pathology
- Presentations: 15
- Moderators:E. Brambilla
- Coordinates: 10/30/2013, 10:30 - 12:00, Bayside 105, Level 1
-
+
MO26.08 - The concomitant presence of echinoderm microtubule associated protein like 4 - anaplastic lymphoma kinase (EML4-ALK) EML4-ALK fusion gene in EGFR-mutant non-small-cell lung cancer (NSCLC) patients treated with erlotinib or chemotherapy in the EURTAC trial
11:10 - 11:15 | Author(s): N. Karachaliou
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.